Deborah Knobelman - Feb 1, 2024 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Role: Chief Financial Officer, Head of Corporate Development
Signature: /s/ Mike Rhee, attorney-in-fact
Stock symbol: SNTI
Transactions as of: Feb 1, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/2/2024, 05:24 PM
Previous filing: Feb 2, 2023
Next filing: Jun 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNTI	Common Stock	Award	$0	+101K	+336.67%	$0.00	131K	Feb 1, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNTI	Stock Option (Right to Buy)	Award	$0	+152K		$0.00	152K	Feb 1, 2024	Common Stock	152K	$0.46	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
F2	The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

Content

The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.